Long COVID is associated with worse cardiovascular fitness. Additional studies are needed to determine if Long COVID is a novel risk factor for incident CVD.

Using symptom and quality of life data, clinical examinations and biofluid proteomics, authors document ocular symptoms persisting from 3 months up to 3 years post-infection.

Immunomodulation could represent a rational therapeutic approach to be evaluated in selected patients.

With support from the European Union, WHO Europe has co‑created Long COVID myth-busters with patients and experts, pairing harmful myths with real stories.

There are no approved treatments for post-COVID-19 condition, a debilitating disease state following SARS-CoV-2 infection that is estimated to affect tens of millions of people.

After surviving Coronavirus Disease 2019 (COVID-19), some people develop symptoms known as post-acute sequelae of COVID-19 (PASC). PASC is an emerging phenomenon yet to be fully understood, and identifying risk factors has been challenging.

A substantial proportion of patients suffer from Post-COVID Syndrome (PCS) with fatigue and impairment of memory and concentration being the most important symptoms.

Some children and young people (CYP) infected with SARS-COV-2 experience impairing symptoms post-infection, known as post-COVID-19 condition (PCC).